3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
tetulomab tetraxetan lu-177
2
osimertinib
2
fludarabine
2
entinostat
2
Pemetrexed
2
Lutetium
2
Carboplatin
2
spartalizumab
1
pembrolizumab
1
nirogacestat
1
interferon gamma-1b
1
gilteritinib
1
ficlatuzumab
1
emvododstat
1
denileukin diftitox
1
atezolizumab
1
Trabectedin
1
Taxes
1
Sunitinib
1
Radiosurgery
1
Oncolytic Virotherapy
1
Nivolumab
1
Lutetium-177
1
Interleukin-2
1
Interferon-gamma
1
Immunotherapy
1
Idarubicin
1
HuMax-IL8
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms by Histologic Type
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled